![]() |
市場調查報告書
商品編碼
2149025
避孕藥市場規模、佔有率、成長率、全球產業分析、區域趨勢以及2026年至2034年的預測Contraceptives Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
2025年全球避孕藥具市場規模為334.2億美元,預計將從2026年的358.3億美元成長至2034年的624.9億美元,預測期內年複合成長率(CAGR)為7.20%。2025年,北美地區佔據全球避孕藥具市場43.17%的佔有率,成為推動市場成長的主要力量。人們對計劃生育的認知不斷提高、避孕產品獲取管道的增加、政府支持的生殖健康計畫以及對有效避孕措施日益成長的需求,都促進了市場的擴張。
避孕是指使用藥物、器械和方法來預防意外懷孕。隨著人們對生殖健康和女性自主權的認知不斷提高,消費者探索更多種類的避孕方式。此外,開發中國家的政府措施也改善人們獲得計劃生育服務和現代避孕方法的途徑。
市場定義和範圍
避孕市場涵蓋用於預防懷孕的藥品和醫療設備。該市場大致依產品、性別和通路細分。產品包括避孕藥具和避孕器械,通路包括零售藥局、醫院藥局和線上通路。該市場針對男性和女性用戶,涵蓋激素類和非激素類避孕方案。
市場動態
促進因素 - 人們對計劃生育的認知提高以及政府的各項舉措
人們對意外懷孕和生殖健康的日益關注推動市場發展。各國政府和醫療機構日益擴大計劃生育宣傳活動、教育計畫,並增加避孕服務的覆蓋範圍。這些努力在開發中國家,人們意識的提高和醫療服務可近性的改善促使現代避孕方法得到廣泛應用。
趨勢 - 低劑量複方口服避孕藥需求不斷成長
低劑量複方口服避孕藥因其雌激素含量低於傳統製劑而備受關注。持續的臨床研究正推動療效和耐受性較佳的避孕藥的研發。同時,數位健康平台和遠端醫療服務也使得人們更容易獲得避孕諮詢和處方箋。
阻礙因素 - 避孕藥的副作用
某些避孕方法的潛在副作用可能會阻礙其廣泛應用。口服避孕藥可能會引起部分使用者出現噁心、頭痛或偏頭痛等症狀。對耐受性、安全性和適用性的擔憂可能會影響消費者的選擇,並導致一些人選擇其他避孕方法。
新冠疫情的影響
新冠疫情擾亂了許多國家的醫療服務、藥品供應鏈、臨床活動和常規生殖保健。出行限制和就醫限制影響了避孕諮詢和避孕藥具的供應。然而,遠距遠端醫療、線上諮詢和電子處方服務的普及為獲取避孕藥具開闢了新的途徑。隨著醫療服務的恢復和計劃生育活動的重啟,避孕藥具的需求也隨之回升。
The global contraceptives market size was valued at USD 33.42 billion in 2025 and is projected to grow from USD 35.83 billion in 2026 to USD 62.49 billion by 2034, exhibiting a CAGR of 7.20% during the forecast period. North America dominated the global contraceptives market with a 43.17% share in 2025. Growing awareness of family planning, increasing access to birth control products, government-supported reproductive health programs, and rising demand for effective pregnancy-prevention methods are supporting market expansion.
Contraception includes drugs, devices, and procedures used to prevent unintended pregnancies. Increasing awareness regarding reproductive health and women's autonomy is encouraging consumers to consider a broader range of contraceptive options. Government initiatives in developing economies are also improving access to family planning services and modern contraceptive methods.
Market Definition and Scope
The contraceptives market includes pharmaceutical and medical-device products used for pregnancy prevention. The market is broadly segmented by product, gender, and distribution channel. Products include contraceptive drugs and contraceptive devices, while distribution channels comprise retail pharmacies, hospital pharmacies, and online channels. The market serves both male and female users and includes hormonal and non-hormonal contraceptive solutions.
Market Dynamics
DRIVER - Rising Awareness and Government Family Planning Initiatives
Increasing awareness about unwanted pregnancies and reproductive health is a major market driver. Governments and healthcare organizations are expanding family planning campaigns, educational programs, and access to contraceptive services. Such initiatives are particularly important in developing countries, where improved awareness and healthcare access can increase adoption of modern birth control methods.
TRENDS - Increasing Demand for Low-Dose Combined Oral Contraceptives
Low-dose combined oral contraceptives are gaining attention because they contain lower quantities of estrogen than older formulations. Continued clinical research is supporting the development of contraceptive options with improved effectiveness and tolerability. At the same time, digital health platforms and telemedicine services are making contraceptive consultation and prescription access more convenient.
RESTRAINT - Side Effects Associated with Contraceptive Products
Potential side effects associated with certain contraceptive methods can restrict adoption. Oral contraceptives may cause symptoms such as nausea, headaches, or migraine in some users. Concerns regarding tolerability, safety, and suitability can influence consumer preferences and encourage some individuals to select alternative contraceptive methods.
Impact of COVID-19
The COVID-19 pandemic disrupted healthcare services, pharmaceutical supply chains, clinical activities, and routine reproductive healthcare in several countries. Restrictions on movement and reduced access to healthcare facilities affected contraceptive consultations and distribution. However, increased adoption of telemedicine, online consultations, and digital prescription services created alternative channels for accessing contraceptive products. As healthcare services normalized, demand recovered alongside renewed family planning activities.
By Product
Contraceptive drugs represent the leading product category due to widespread awareness, established distribution networks, and availability of oral contraceptive products. Increasing pharmaceutical development and product launches are supporting the segment. Meanwhile, contraceptive devices are expected to expand as consumers seek long-acting and alternative birth control options.
By Gender
The market is divided into male and female segments. The female segment continues to represent a significant portion of demand due to the broad availability of female contraceptive products and continuing efforts to reduce unintended pregnancies. The male segment is also gaining attention as pharmaceutical companies and researchers develop additional male contraceptive solutions.
By Distribution Channel
Retail pharmacies are expected to maintain the leading position because of their extensive distribution networks and convenient consumer access. Hospital pharmacies remain important for contraceptive devices and prescription-based products. Online channels are gaining momentum as digital healthcare platforms improve access to consultations, prescriptions, and contraceptive products.
Regional Analysis
North America
North America dominated the market in 2025 with a market value of USD 9.71 billion. Strong contraceptive awareness, established healthcare infrastructure, extensive product availability, and increasing attention toward preventing unintended pregnancies support regional demand.
Europe
Europe is expected to witness steady growth, supported by clinical research, contraceptive adoption, healthcare initiatives, and increasing availability of modern birth control products. The region is projected to grow at a 5.6% CAGR during the forecast period.
Asia Pacific
Asia Pacific is expected to experience significant growth due to rising awareness regarding family planning, increasing healthcare accessibility, and government initiatives promoting reproductive health. Growing participation of manufacturers in Asian markets is also creating new opportunities.
U.S.
The U.S. market benefits from high contraceptive awareness, established healthcare infrastructure, government-supported reproductive health initiatives, and broad availability of contraceptive products.
Japan
The contraceptives market in Japan is expected to reach USD 1.05 billion by 2025, supported by established healthcare services and increasing availability of contraceptive options.
China
China is expected to witness strong market growth, supported by healthcare development, increasing awareness, and improving access to family planning products and services.
Competitive Landscape
The market is characterized by the presence of pharmaceutical companies, medical-device manufacturers, and specialized reproductive-health companies. Leading participants focus on product development, regulatory approvals, distribution expansion, and digital healthcare partnerships. Key companies include Pfizer Inc., Bayer AG, CooperSurgical Inc., The Female Health Company, Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Mayer Laboratories, Inc., Church & Dwight Co., Inc., and Medisafe Distribution Inc.
Key Industry Developments
Recent industry activity has focused on prescription delivery, telemedicine, digital contraceptive solutions, and novel pharmaceutical formulations. Mayne Pharma received U.S. FDA approval for NEXTSTELLIS in 2021, while Emme expanded its contraceptive technology platform into prescription delivery and telemedicine services. Other developments include digital fertility-management and non-hormonal contraceptive products.
Report Coverage
The contraceptives market report provides qualitative and quantitative analysis of market size and market value across product categories, gender groups, distribution channels, and major geographic regions. It examines market drivers, restraints, trends, growth opportunities, competitive strategies, product launches, clinical developments, and regional market conditions. The report also profiles leading companies operating in the global contraceptives industry.
Conclusion
The global contraceptives market is projected to expand from USD 33.42 billion in 2025 to USD 35.83 billion in 2026 and USD 62.49 billion by 2034. Increasing awareness of reproductive health, government-supported family planning programs, continued development of contraceptive drugs and devices, and growing access through retail and digital healthcare channels will support market growth. North America will remain a major market, while Asia Pacific is expected to offer substantial opportunities as healthcare access and awareness improve. Continued innovation in low-dose, non-hormonal, male, and digitally supported contraceptive solutions is expected to strengthen the industry's long-term outlook.
By Product
By Gender
By Distribution Channel
By Geography